Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
The inhibition of Il1β synthesis mediated by a novel pyridine-sulfonamide compound protects against the progression of metabolic dysfunction-associated steatotic liver disease.
Ángela Berlana, Esther Rey, Elena Fresno-Ventura, Patricia Gomez-Gutierrez, Miguel Vega, Carmelo García-Monzón, Águeda González-Rodríguez
Published: 202610.1016/j.biopha.2026.119052
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the leading cause of chronic liver disease worldwide. The increasing MASLD burden and the lack of effective therapies underscore the urgent need for new therapeutic approac…
Preview only. Read the full abstract at the source